Please assess the completion status of the following clinical trial:

Trial Title: The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed Informed Consent Form~2. Age greater than or equal to 18 years~3. Histologically or cytologically documented, incurable, advanced solid malignancy that has progressed on, or failed to respond to, at least one prior systemic therapy~4. Evaluable or measurable disease per RECIST 1.1~5. ECOG performance status of 0 or 1~6. In the dose expansion stage, patients with BRCA (breast carcinoma) mutation will be enrolled. Patients with breast cancer, ovarian cancer and prostate cancer are preferred.~Exclusion Criteria:~1. Inadequate haematologic and organ function, defined by the following (haematologic parameters must be assessed greater than or equal to 14 days after a prior treatment, if any):~   1. Absolute neutrophil count \<1500 cells/uL~  2. Haemoglobin \<9 g/dL~  3. Total bilirubin \>1.5 x the ULN, with documented liver metastases total bilirubin \>3 x the ULN .~  4. AST and/or ALT \>2.5 x the ULN, with documented liver metastases AST and/or ALT levels \> 5 x the ULN.~  5. Serum creatinine \> 1.5 x the ULN, or creatinine clearance \< 50 mL/min based on a documented 24-hour urine collection.~  6. International normalized ratio (INR) \> 1.5 x the ULN or activated partial thromboplastin time (aPTT) \>1.5 x the ULN The INR applies only to patients who do not receive therapeutic anti-coagulation.~2. Any anti-cancer therapy, including chemotherapy, hormonal therapy, biologic therapy, radiotherapy within 4 weeks prior to initiation of study treatment with the following exceptions:~   1. Hormonal therapy with gonadotropin-releasing hormone (GnRH) agonists for prostate cancer~  2. Hormone-replacement therapy or oral contraceptives~  3. Palliative radiation to bone metastases \> 2 weeks prior to Day 1~3. Adverse events from prior anti-cancer therapy that have not resolved to CTCAE Grade less than or equal to 1, except for alopecia~4. Clinical significant active infection~5. Known clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis~6. Known human immunodeficiency virus infection~7. New York Heart Association (NYHA) Class II or greater congestive heart failure; history of myocardial infarction or unstable angina within 6 months prior to Day 1; history of stroke or transient ischemic attack within 6 months prior to Day 1~8. Active or untreated brain metastasis~9. Pregnant (positive pregnancy test) or lactating women~10. Male or female patients of child-producing potential unwilling to use double barrier contraception: condoms, sponge, foams, jellies, diaphragm or intrauterine device (IUD), contraceptives (oral, injectable or parenteral), implanon, or other avoidance of pregnancy measures during the study and for 90 days after the last day of treatment~11. Inability to take oral medication, prior surgical procedures affecting absorption, or active peptic ulcer disease~12. Inability to comply with study and follow-up procedures~13. Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the patient at high risk from treatment complications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IMP4297 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).